# REGENXBIO Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/REGENXBIO Inc.).

## Overview

REGENXBIO Inc. is a U.S.-based biotechnology company focused on adeno-associated virus (AAV) gene therapy. It develops and licenses its NAV Technology Platform and related gene therapy programs, while also earning royalties and collaboration revenue from partnered products and services.

## Products & services

• NAV Technology Platform licensing
• AAV gene therapy product candidates
• Royalty revenue from partnered therapies
• Collaboration and development services
• Manufacturing process and assay IP

- **Platform licensing** (55%) — Licenses of the NAV Technology Platform and related intellectual property to biotech and pharma partners.
- **Royalties** (35%) — Royalty income tied mainly to sales of partnered gene therapy products such as Zolgensma and Itvisma.
- **Collaboration services** (10%) — Development, manufacturing, and other service work performed under collaboration agreements.

- NAV Technology Platform licensing
- AAV gene therapy product candidates
- Royalty revenue from partnered therapies
- Collaboration and development services
- Manufacturing process and assay IP

## Customers

REGENXBIO sells primarily to a small number of biotechnology and pharmaceutical collaboration partners rather than to end patients. Its revenue comes from licensees, royalty payers, and partners that use the NAV platform to develop and commercialize gene therapies. The company also supports collaborators with development and manufacturing services tied to specific programs.

- **Biopharma licensees** (primary) — Companies licensing NAV Technology Platform rights for internal R&D and therapeutic development.
- **Commercial partners** (primary) — Partners that market licensed products and generate royalty streams for REGENXBIO.
- **Collaboration partners** (secondary) — Partners paying for development, manufacturing, and service work under collaboration agreements.

- Biopharma licensees using NAV for gene therapy development
- Royalty-paying partners commercializing licensed products
- Collaborators funding program development and manufacturing work
- Partners seeking access to AAV delivery IP and know-how
- Customers concentrated in a few large strategic counterparties

## Geography

REGENXBIO is headquartered in Rockville, Maryland, and operates as a U.S.-based company. Its revenue exposure is tied to global partner commercialization, especially royalties from products sold in multiple territories through licensees. The business is therefore geographically driven more by partner sales footprints and regulatory approvals than by direct end-market operations.

- Headquartered in Rockville, Maryland, United States
- Revenue depends on partner commercialization across multiple territories
- Royalty exposure is linked to global sales of licensed products
- Manufacturing and development capabilities support clinical supply needs
- Geography matters because partner sales drive royalty mix

## Strategy

REGENXBIO’s strategy centers on advancing its NAV AAV platform, expanding partnered gene therapy programs, and converting intellectual property into recurring royalty and licensing revenue. The company also seeks to progress its own product candidates and manufacturing capabilities so it can participate in both partnered and proprietary value creation. This model aims to combine platform monetization with long-duration upside from clinical programs.

- **Grow NAV platform partnerships** (short-term) — Licensing broadens the installed base of programs that can generate upfront, milestone, and royalty economics.
- **Advance proprietary gene therapy candidates** (medium-term) — Internal programs provide potential long-term product revenue beyond platform royalties.
- **Support manufacturing scalability** (medium-term) — AAV manufacturing capability is critical for clinical supply, quality, and future commercialization.

- Monetize NAV platform through licenses and collaborations
- Advance internal gene therapy candidates toward approval
- Expand royalty streams from partnered commercial products
- Use manufacturing and assay IP to support clinical supply
- Build value from both platform and product pipelines

## Risks

The business depends on a small number of partners and on the success of a limited set of gene therapy programs, so revenue can be volatile and concentrated. Clinical, regulatory, manufacturing, and intellectual property risks are central because the company’s value depends on proving safety, efficacy, and scalable AAV production. As a biotechnology company, it also faces funding and commercialization risk if product development or partner adoption slows.

- **Customer concentration** [high] — Most revenue comes from a very small number of partners, so loss or delay from one partner can materially reduce revenue.
- **Clinical development failure** [high] — Lead product candidates must prove safety and efficacy in trials before commercialization is possible.
- **Regulatory approval risk** [high] — Gene therapy endpoints and follow-up requirements can delay or prevent approval.
- **Manufacturing and quality risk** [medium] — AAV vector production must meet clinical and commercial supply requirements with consistent yield and purity.
- **Intellectual property risk** [high] — The platform depends on patents and third-party license rights that can be challenged or limited.

- Revenue concentration in a few licensees and collaborators
- Clinical trials may fail to show safety or efficacy
- Regulatory approval timing is uncertain
- AAV manufacturing scale-up and yield remain execution risks
- IP disputes or license limits could constrain the platform
- Funding needs may rise before product commercialization

## Accounting

Revenue recognition is a key accounting area because the company records license, royalty, and service revenue under collaboration agreements, often with contingent milestones and significant financing components. Royalty revenue can fluctuate with partner sales, while upfront license fees and service revenue depend on contract terms and performance obligations. Investors should also watch estimates tied to royalty monetization liabilities, interest income from licensing, and any impairment or valuation judgments around long-lived intangible assets and contract-related balances.

- **ASC 606 revenue recognition** — Can shift revenue between periods and create volatility
- **Significant financing components** — Affects reported interest income from licensing
- **Royalty monetization liabilities** — Influences leverage, cash flow, and earnings presentation
- **IP and patent-related estimates** — Could affect asset carrying values and expense recognition

- License revenue depends on performance obligations and milestone timing
- Royalty revenue tracks partner sales and can swing quarter to quarter
- Significant financing components affect interest income from licensing
- Royalty monetization liabilities affect interest expense and cash flow
- Patent and IP-related assets require ongoing valuation and impairment review

---

*Last updated: 2026-04-29T04:51:35.954463+00:00*